Response Biomedical Completes Share Consolidation | GenomeWeb

NEW YORK (GenomeWeb News) – Response Biomedical has completed a 20-for-one share consolidation, the Vancouver, British Columbia-based firm said yesterday after the close of the market.

The diagnostics firm said that it expects its post-consolidation common shares will begin trading on the Toronto Stock Exchange and the OTC Bulletin Board in the US on Sept. 26. It announced the share consolidation last month.

The shares were trading at $.08 on the OTC Bulletin Board, with no shares trading hands, early Tuesday afternoon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.